These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
204 related items for PubMed ID: 20019334
1. Overexpression of dimethylarginine dimethylaminohydrolase protects against cerebral vascular effects of hyperhomocysteinemia. Rodionov RN, Dayoub H, Lynch CM, Wilson KM, Stevens JW, Murry DJ, Kimoto M, Arning E, Bottiglieri T, Cooke JP, Baumbach GL, Faraci FM, Lentz SR. Circ Res; 2010 Feb 19; 106(3):551-8. PubMed ID: 20019334 [Abstract] [Full Text] [Related]
2. Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Dayal S, Rodionov RN, Arning E, Bottiglieri T, Kimoto M, Murry DJ, Cooke JP, Faraci FM, Lentz SR. Am J Physiol Heart Circ Physiol; 2008 Aug 19; 295(2):H816-25. PubMed ID: 18567702 [Abstract] [Full Text] [Related]
3. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Dayoub H, Rodionov RN, Lynch C, Cooke JP, Arning E, Bottiglieri T, Lentz SR, Faraci FM. Stroke; 2008 Jan 19; 39(1):180-4. PubMed ID: 18063827 [Abstract] [Full Text] [Related]
4. Overexpression of dimethylarginine dimethylaminohydrolase 1 protects from angiotensin II-induced cardiac hypertrophy and vascular remodeling. Kopaliani I, Jarzebska N, Billoff S, Kolouschek A, Martens-Lobenhoffer J, Bornstein SR, Bode-Böger SM, Ragavan VN, Weiss N, Mangoni AA, Deussen A, Rodionov RN. Am J Physiol Heart Circ Physiol; 2021 Nov 01; 321(5):H825-H838. PubMed ID: 34533401 [Abstract] [Full Text] [Related]
5. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Dayal S, Arning E, Bottiglieri T, Böger RH, Sigmund CD, Faraci FM, Lentz SR. Stroke; 2004 Aug 01; 35(8):1957-62. PubMed ID: 15178827 [Abstract] [Full Text] [Related]
6. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Hu X, Xu X, Zhu G, Atzler D, Kimoto M, Chen J, Schwedhelm E, Lüneburg N, Böger RH, Zhang P, Chen Y. Circulation; 2009 Dec 01; 120(22):2222-9. PubMed ID: 19917889 [Abstract] [Full Text] [Related]
7. Plasma asymmetric and symmetric dimethylarginine in a rat model of endothelial dysfunction induced by acute hyperhomocysteinemia. Magné J, Huneau JF, Borderie D, Mathé V, Bos C, Mariotti F. Amino Acids; 2015 Sep 01; 47(9):1975-82. PubMed ID: 25792109 [Abstract] [Full Text] [Related]
8. Effect of Mthfr genotype on diet-induced hyperhomocysteinemia and vascular function in mice. Devlin AM, Arning E, Bottiglieri T, Faraci FM, Rozen R, Lentz SR. Blood; 2004 Apr 01; 103(7):2624-9. PubMed ID: 14630804 [Abstract] [Full Text] [Related]
9. Protective vascular and cardiac effects of inducible nitric oxide synthase in mice with hyperhomocysteinemia. Dayal S, Blokhin IO, Erger RA, Jensen M, Arning E, Stevens JW, Bottiglieri T, Faraci FM, Lentz SR. PLoS One; 2014 Apr 01; 9(9):e107734. PubMed ID: 25226386 [Abstract] [Full Text] [Related]
10. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Hu X, Atzler D, Xu X, Zhang P, Guo H, Lu Z, Fassett J, Schwedhelm E, Böger RH, Bache RJ, Chen Y. Arterioscler Thromb Vasc Biol; 2011 Jul 01; 31(7):1540-6. PubMed ID: 21493890 [Abstract] [Full Text] [Related]
11. Reduced Renal Methylarginine Metabolism Protects against Progressive Kidney Damage. Tomlinson JA, Caplin B, Boruc O, Bruce-Cobbold C, Cutillas P, Dormann D, Faull P, Grossman RC, Khadayate S, Mas VR, Nitsch DD, Wang Z, Norman JT, Wilcox CS, Wheeler DC, Leiper J. J Am Soc Nephrol; 2015 Dec 01; 26(12):3045-59. PubMed ID: 25855779 [Abstract] [Full Text] [Related]
12. Genetic variation in the dimethylarginine dimethylaminohydrolase 1 gene (DDAH1) is related to asymmetric dimethylarginine (ADMA) levels, but not to endothelium-dependent vasodilation. Lind L, Ingelsson E, Kumar J, Syvänen AC, Axelsson T, Teerlink T. Vasc Med; 2013 Aug 01; 18(4):192-9. PubMed ID: 23892448 [Abstract] [Full Text] [Related]
17. Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia. Dayal S, Wilson KM, Leo L, Arning E, Bottiglieri T, Lentz SR. Blood; 2006 Oct 01; 108(7):2237-43. PubMed ID: 16804115 [Abstract] [Full Text] [Related]
18. ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy. Rodionov RN, Heinrich A, Brilloff S, Jarzebska N, Martens-Lobenhoffer J, Bode-Böger SM, Todorov VT, Hugo CPM, Weiss N, Hohenstein B. Atheroscler Suppl; 2017 Nov 01; 30():319-325. PubMed ID: 29096857 [Abstract] [Full Text] [Related]
19. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Arterioscler Thromb Vasc Biol; 2000 Jun 01; 20(6):1557-64. PubMed ID: 10845872 [Abstract] [Full Text] [Related]
20. Dimethylarginine Dimethylaminohydrolase 1 Protects Against High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice. Li T, Feng R, Zhao C, Wang Y, Wang J, Liu S, Cao J, Wang H, Wang T, Guo Y, Lu Z. Antioxid Redox Signal; 2017 Apr 10; 26(11):598-609. PubMed ID: 27565538 [Abstract] [Full Text] [Related] Page: [Next] [New Search]